Wide Ranks

ACXP

Acurx Pharmaceuticals, Inc.

1.15

Top Statistics
Market Cap 19 M Forward PE -0.5558 Revenue Growth 0.00 %
Current Ratio 2.09 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 6 M Total Cash Per Share 0.3920 Total Debt
Total Debt To Equity Current Ratio 2.09 Book Value Per Share 0.3230
All Measures
Short Ratio 1259.00 % Message Board Id finmb_558025934 Shares Short Prior Month 491741
Return On Equity -3.47 City Staten Island Uuid f968c125-b6b8-3075-a306-c4b0f5d5bed0
Previous Close 1.14 First Trade Date Epoch Utc 1 B Book Value 0.3230
Beta -1.72 Volume 252428 Price To Book 3.54
Fifty Two Week Low 1.00 Total Cash Per Share 0.3920 Shares Short Previous Month Date 1 B
Target Median Price 11.57 Max Age 86400 Recommendation Mean 2.00
Sand P52 Week Change 0.3133 Target Mean Price 11.19 Net Income To Common -16729286
Short Percent Of Float 0.0343 Implied Shares Outstanding 16 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 262430 Average Volume10days 262430
Total Cash 6 M Next Fiscal Year End 1 B Held Percent Insiders 0.1480
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.14 Target Low Price 10.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.85 Open 1.13 Free Cashflow -5961016
State NY Dividend Yield 0.00 % Return On Assets -1.32
Time Zone Short Name EST Trailing Eps -1.09 Day Low 1.00
Address1 259 Liberty Avenue Shares Outstanding 16 M Price Hint 4
Target High Price 12.00 Website https://www.acurxpharma.com 52 Week Change -0.6747
Average Volume 77543 Forward Eps -1.55 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 203.40 % Is_sp_500 False
Regular Market Day High 1.15 Profit Margins 0.00 % Fifty Two Week High 5.28
Day High 1.15 Shares Short 474480 Regular Market Open 1.13
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0292 Operating Cashflow -12234498 Currency USD
Time Zone Full Name America/New_York Market Cap 19 M Is_nasdaq_100 False
Zip 10305 Quote Type EQUITY Industry Biotechnology
Long Name Acurx Pharmaceuticals, Inc. Regular Market Day Low 1.00 Held Percent Institutions 0.1196
Current Price 1.15 Financial Currency USD Current Ratio 2.09
Industry Disp Biotechnology Number Of Analyst Opinions 3 Country United States
Float Shares 13 M Two Hundred Day Average 2.18 Enterprise Value 23 M
Forward PE -0.5558 Regular Market Volume 252428 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.

The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.

Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.